These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 28554216)

  • 1. Nanoparticulation improves bioavailability of Erlotinib.
    Yang KM; Shin IC; Park JW; Kim KS; Kim DK; Park K; Kim K
    Drug Dev Ind Pharm; 2017 Sep; 43(9):1557-1565. PubMed ID: 28554216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of nano-particulated, water-soluble erlotinib against intracranial metastases of EGFR-mutant lung cancer.
    Kim DH; Choi YJ; Sung KJ; Yoo SA; Sung YH; Kim JK; Choi CM; Yun M; Lee EY; Jin YS; Cook S; Rho JK; Lee JC
    Mol Oncol; 2018 Dec; 12(12):2182-2190. PubMed ID: 30350450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticulated docetaxel exerts enhanced anticancer efficacy and overcomes existing limitations of traditional drugs.
    Choi J; Ko E; Chung HK; Lee JH; Ju EJ; Lim HK; Park I; Kim KS; Lee JH; Son WC; Lee JS; Jung J; Jeong SY; Song SY; Choi EK
    Int J Nanomedicine; 2015; 10():6121-32. PubMed ID: 26457052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nanosystem for water-insoluble drugs prepared by a new technology, nanoparticulation using a solid lipid and supercritical fluid.
    Park JW; Yun JM; Lee ES; Youn YS; Kim KS; Oh YT; Oh KT
    Arch Pharm Res; 2013 Nov; 36(11):1369-76. PubMed ID: 23780798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HA/HSA co-modified erlotinib-albumin nanoparticles for lung cancer treatment.
    Shen Y; Li W
    Drug Des Devel Ther; 2018; 12():2285-2292. PubMed ID: 30087553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells.
    Patel K; Doddapaneni R; Patki M; Sekar V; Bagde A; Singh M
    AAPS PharmSciTech; 2019 Mar; 20(3):135. PubMed ID: 30830506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation.
    Zhou X; Tao H; Shi KH
    Drug Des Devel Ther; 2018; 12():1-8. PubMed ID: 29296076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of sorafenib loaded nanoparticles to improve oral bioavailability using a quality by design approach.
    Park SY; Kang Z; Thapa P; Jin YS; Park JW; Lim HJ; Lee JY; Lee SW; Seo MH; Kim MS; Jeong SH
    Int J Pharm; 2019 Jul; 566():229-238. PubMed ID: 31136778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supersaturation of zafirlukast in fasted and fed state intestinal media with and without precipitation inhibitors.
    Madsen CM; Boyd B; Rades T; Müllertz A
    Eur J Pharm Sci; 2016 Aug; 91():31-9. PubMed ID: 27260089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability.
    Dora CP; Trotta F; Kushwah V; Devasari N; Singh C; Suresh S; Jain S
    Carbohydr Polym; 2016 Feb; 137():339-349. PubMed ID: 26686138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solid lipid nanoparticles of anticancer drug andrographolide: formulation, in vitro and in vivo studies.
    Parveen R; Ahmad FJ; Iqbal Z; Samim M; Ahmad S
    Drug Dev Ind Pharm; 2014 Sep; 40(9):1206-12. PubMed ID: 23826860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer.
    Momin MM; Zaheer Z; Zainuddin R; Sangshetti JN
    Artif Cells Nanomed Biotechnol; 2018 Aug; 46(5):1064-1075. PubMed ID: 28758795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation.
    Devasari N; Dora CP; Singh C; Paidi SR; Kumar V; Sobhia ME; Suresh S
    Carbohydr Polym; 2015 Dec; 134():547-56. PubMed ID: 26428157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver.
    Varan G; Akkın S; Demirtürk N; Benito JM; Bilensoy E
    J Drug Target; 2021 Apr; 29(4):439-453. PubMed ID: 33210947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer.
    Bakhtiary Z; Barar J; Aghanejad A; Saei AA; Nemati E; Ezzati Nazhad Dolatabadi J; Omidi Y
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1244-1253. PubMed ID: 28323493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
    Sawant KK; Patel MH; Patel K
    Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between fed gastric media (Ensure Plus®) and different hypromellose based caffeine controlled release tablets: comparison and mechanistic study of caffeine release in fed and fasted media versus water using the USP dissolution apparatus 3.
    Franek F; Holm P; Larsen F; Steffansen B
    Int J Pharm; 2014 Jan; 461(1-2):419-26. PubMed ID: 24342711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility.
    Mou D; Chen H; Wan J; Xu H; Yang X
    Int J Pharm; 2011 Jul; 413(1-2):237-44. PubMed ID: 21540090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced oral bioavailability of lurasidone by self-nanoemulsifying drug delivery system in fasted state.
    Miao Y; Sun J; Chen G; Lili R; Ouyang P
    Drug Dev Ind Pharm; 2016 Aug; 42(8):1234-40. PubMed ID: 26582334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.